Geraniol treatment of irritable bowel syndrome patients

ISRCTN ISRCTN47041881
DOI https://doi.org/10.1186/ISRCTN47041881
Secondary identifying numbers IBS-22-05
Submission date
09/07/2018
Registration date
19/07/2018
Last edited
23/08/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Irritable bowel syndrome (IBS) is a disease that can cause bloating, diarrhoea, constipation and intestinal discomfort. It can also lead to dysbiosis, which is where there is a disturbance or imbalance in the microbes that live in the gut (gut microbiota), along with inflammation of the intestines. There is not yet an effective way to treat IBS.
Essential oils, which are natural oils that come from plants, are considered to be antibacterial and anti-inflammatory, and are known to have an effect on gut microbiota. Geraniol is a compound that comes from essential oils from plants such as lemongrass and rose, and has been shown to have strong anti-inflammatory properties. Additionally, geraniol has been shown to be effective against colitis (a symptom of IBD) and dysbiosis in studies on mice.
As geraniol is safe for humans, we aimed to determine whether geraniol was effective at reducing inflammation and dysbiosis in patients with IBD.

Who can participate?
Patients with IBS aged 18-65, weighing between 48 and 104 kg with a BMI of less than 27.

What does the study involve?
Participants will be asked to take capsules of geraniol orally daily for 4 weeks (geraniol dose depends on body weight) and will be asked to provide fecal samples before treatment, after 4 weeks of treatment and 4 weeks after treatment has ended.

What are the possible benefits and risks of participating?
The possible benefit to participants of taking part is that previous studies have shown that similar treatments that affect gut microbiota lead to improvement of IBD symptoms such as bloating and diarrhoea; therefore, this may also be the case for geraniol treatment. There are no known risks to participants of taking part.

Where is the study run from?
1. Inflammatory Bowel Disease Unit, S. Orsola-Malpighi Hospital, Bologna, Italy (lead centre)
2. Spedali Civili di Brescia, Brescia, Italy (satellite centre)

When is the study starting and how long is it expected to run for?
January 2015 to December 2017
Who is funding the study?
1. University of Bologna (Italy)
2. Xeda International SA (France)

Who is the main contact?
Professor Enzo Spisni
enzo.spisni@unibo.it

Contact information

Prof Enzo Spisni
Scientific

Via Selmi 3
Bologna
40126
Italy

ORCiD logoORCID ID 0000-0002-8525-2981

Study information

Study designInterventional open label non-randomised multi-centre pilot study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet ISRCTN47041881_PIS.docx
Scientific titleEffect of dietary geraniol on intestinal dysbiosis in irritable bowel syndrome patients
Study acronymIBS-Ge-OH
Study objectivesGeraniol could be a food supplement with anti-inflammatory and anti-dysbiotic activity in irritable bowel syndrome (IBS) patients.
Ethics approval(s)Ethics Committee of the AOU Policlinico S. Orsola-Malpighi, 29/10/2013, CE code 100/2013/U/Sper
Ethics Committee of the ASST Spedali Civili di Brescia, 03/06/2015, CE code NP2047
Health condition(s) or problem(s) studiedIrritable bowel syndrome (IBS)
InterventionParticipants underwent geraniol treatment for a period of 4 weeks and was taken daily at a maximum dose of 8 mg/Kg/day. Geraniol was provided in capsules containing 150 mg geraniol and 160 mg soy lecithin. The number of capsules given was calculated depending on the body weight of partcipants.
1. Participants weighing 48-59 kg were given a dose of 3 capsules per day
2. Participants weighing 60-74 kg were given a dose of 4 capsules per day
3. Participants weighing 75-89 kg were given a dose of 5 capsules per day
4. Participants weighing 90-104 kg were given a dose of 6 capsules per day.
After taking geraniol daily for 4 weeks, there was 4 weeks of follow up - a 'wash out' period where geraniol was not taken.
Participants were asked to provide fecal samples before treatment, after 4 weeks of treatment and 4 weeks after treatment was complete.
Intervention typeSupplement
Primary outcome measureChanges in fecal microbiota composition after 4 weeks of geraniol administration was measured through phylogenetic DNA array analysis of fecal samples before starting geraniol treatment (visit 1), after 4 weeks of treatment (visit 2) and 4 weeks after treatment finished (visit 3, after 4 weeks of wash out).
Secondary outcome measures1. Fecal microbial composition in patients with IBS was measured using phylogenetic DNA array analysis of fecal samples before starting geraniol treatment (visit 1).
2. Changes in the microbiota-immune system axis was measured through Luminex analysis of plasma for the levels of cytokines and chemokines involved in the T helper 17 pathway (IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-γ, sCD40L, TNF-α). This was measured before starting geraniol treatment (visit 1), after 4 weeks of treatment (visit 2) and 4 weeks after treatment finished (visit 3).
Overall study start date01/01/2015
Completion date31/12/2017

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit65 Years
SexBoth
Target number of participants25
Total final enrolment19
Key inclusion criteria1) Signature of informed consent
2) Irritable bowel syndrome, meeting the Roma III criteria for diagnosis of IBS
3) Body weight between 46 kg and 100 kg, with BMI less than 27
4) Aged 18-65 years
Key exclusion criteria1. Taken steroid anti-inflammatory drugs, antibiotics or supplements and/or functional foods containing probiotics or prebiotics in the months prior to enrolment
2. Pregnancy, suspected pregnancy or breastfeeding
3. Diagnosed with IBD
4. Coeliac disease
5. Severe systemic disease
6. Lactose intolerant
7. Known food allergies
8. Known or suspected hypersensitivity to geraniol or soy
9. Serious concomitant diseases that contraindicate participation in the study (in the opinion of the investigator)
10. Use of experimental drugs in the 2 months prior to enrolment
Date of first enrolment01/03/2015
Date of final enrolment30/10/2017

Locations

Countries of recruitment

  • Italy

Study participating centres

IBD Unit
S. Orsola Hospital, Pad. 5, Via Massarenti 49
Bologna
40126
Italy
Gastroenterology Unit
Spedali Civili di Brescia, Piazzale Spedali Civili, 1
Brescia
25123
Italy

Sponsor information

University of Bologna
University/education

Via Selmi 3
Bologna
40126
Italy

Website http://www.unibo.it/en/homepage
ROR logo "ROR" https://ror.org/01111rn36
Xeda international
Industry

Route nationale 7 - ZAC LA CRAU -
SAINT ANDIOL
13670
France

Website https://www.xeda.com/

Funders

Funder type

Not defined

Università di Bologna
Government organisation / Local government
Alternative name(s)
University of Bologna, UNIBO
Location
Italy

Results and Publications

Intention to publish date01/09/2018
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot expected to be made available
Publication and dissemination planWe intend to publish in BMC Complementary and Alternative Medicine.
IPD sharing planData was collected in pseudonymous form and explicit consent to provide raw data to third parties not involved in the clinical trial was not given by the patients. The explicit consent was given only to publish data in an aggregate form.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet 02/04/2019 No Yes
Results article results 19/12/2018 07/11/2019 Yes No
Results article 10/10/2022 23/08/2023 Yes No

Additional files

ISRCTN47041881_PIS.docx
Uploaded 02/04/2019

Editorial Notes

23/08/2023: Publication reference added.
23/11/2020: Internal review.
07/11/2019: The following changes were made to the trial record:
1. Publication reference added.
2. The total final enrolment was added.
24/05/2019: Internal review.
02/04/2019: The participant information sheet has been uploaded.